来曲唑治疗绝经后乳腺癌所致骨流失的组合评估方法研究  

Study on the Combined Evaluation Method of Letrozole in the Treatment of Postmenopausal Bone Loss Caused by Breast Cancer

作　　者：袁文博 姚荧 谢冰雪 赵筱倩 徐银莹 Yuan Wenbo;Yao Ying;Xie Bingxue;Zhao Xiaoqian;Xu Yinying(Pharmacy Department,Wuxi Obstetrics and Gynecology Hospital Affiliated to Jiangnan University,Wuxi,Jiangsu 214002;Breast Department,Wuxi Obstetrics and Gynecology Hospital Affiliated to Jiangnan University,Wuxi,Jiangsu 214002)

机构地区：[1]江南大学附属无锡妇产医院药学部,江苏无锡214002 [2]江南大学附属无锡妇产医院乳腺科,江苏无锡214002

出　　处：《科技与健康》2024年第21期1-5,共5页Technology and Health

基　　金：无锡市科技发展资金项目(N20202025);无锡市卫生健康委重大项目(Z202205);江苏省研究型医院学会精益化治疗专委会课题(JY202016);江苏省药学会恒瑞医院药学基金课题(H202031)。

摘　　要：探讨骨密度评分(bone mineral density-Tscore,BMD-T)结合6号染色体(estrogen receptor 1,ESR1)基因多态性的组合评估方法用于非骨质疏松的绝经后乳腺癌人群长期使用来曲唑骨流失风险评估的可行性。选取2020年7月—2021年5月就诊于江南大学附属无锡妇产医院的240例绝经后女性乳腺癌患者为研究对象,所有患者仅使用曲唑片2.5 mg/天进行内分泌治疗。将患者随机分入BMD-T评分组(A)、ESR1基因多态性评估组(B)、组合评估高风险组、组合评估低风险组,每组各60例,高低风险人数比例为1:1。半年、一年后检查骨密度,两两比较各组骨流失发生率的差异。结果表明,组合评估高风险组在一年后能覆盖最多的骨流失人群(30%)。研究发现,BMD-T评分在﹣1.0以上的人群不需要进行ESR1基因多态性评估;BMD-T评分为﹣2.5~﹣1.0的人群使用组合评估高风险策略具有可行性。To explore the feasibility of the combined assessment method of bone mineral density score(BMD-T)and ESR1 gene polymorphism for long-term use of letrozole in non osteoporosis postmenopausal breast cancer population.240 postmenopausal women with breast cancer who visited Wuxi Obstetrics and Gynecology Hospital Affiliated to Jiangnan University from July 2020 to May 2021 were selected as the study subjects.Patients will be randomly divided into BMD-T evaluation group(A),ESR1 gene polymorphism evaluation group(B),combination evaluation high-risk group,and combination evaluation low-risk group,with 60 cases in each group and a 1:1 ratio of high-risk and low-risk individuals.Bone density was checked six months and one year later,and the differences in bone loss rates between the groups were compared pairwise.The results showed that the combination assessment of high-risk groups could cover the largest number of bone loss populations(30%)after one year.Research has found that individuals with BMD-T scores above﹣1.0 do not require ESR1 gene polymorphism assessment;The use of combination assessment for high-risk strategies is feasible for populations with BMD-T scores ranging from﹣2.5 to﹣1.0.

关 键 词：芳香化酶抑制剂 基因多态性 骨流失 内分泌治疗 

分 类 号：R737.9[医药卫生—肿瘤]